/PRNewswire/ Nuance Pharma ("the Company") announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application.
/PRNewswire/ Nuance Pharma ("the Company") announces the completion of dosing for all HNVs in the Phase I clinical study of its novel Ketorolac for IV.